What is the treatment and prevention of impetigo?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Impetigo: Treatment and Prevention

Overview and Etiology

Impetigo is a highly contagious superficial bacterial skin infection most commonly affecting children aged 2-5 years, caused by Staphylococcus aureus and/or Streptococcus pyogenes, requiring antibiotic therapy for optimal management. 1, 2

The infection presents in two forms:

  • Nonbullous impetigo (70% of cases): Characterized by honey-colored crusts, typically on the face and extremities 2
  • Bullous impetigo (30% of cases): Caused exclusively by S. aureus, presenting with large flaccid bullae, often in intertriginous areas 2

The pathogenesis involves initial colonization of unbroken skin (approximately 10 days before lesions appear), followed by inoculation through minor trauma, abrasions, or insect bites 3


Treatment Algorithm

For Limited/Localized Disease

First-line treatment is topical mupirocin 2% ointment applied three times daily for 5-7 days. 1, 4

  • Mupirocin demonstrates 71% clinical efficacy versus 35% for placebo, with 94% pathogen eradication rates 4
  • Alternative: Retapamulin 1% ointment applied twice daily for 5 days 1
  • Both agents provide coverage against S. aureus and S. pyogenes 1

Important caveat: Topical therapy is appropriate when lesions are few in number and confined to small areas 1, 5

For Extensive Disease or When Topical Therapy Fails

Oral antibiotics are indicated when impetigo is extensive, involves multiple sites, topical therapy is impractical, topical treatment has failed, or systemic symptoms are present. 1, 5

For Methicillin-Susceptible S. aureus (MSSA):

  • Dicloxacillin: 250 mg four times daily (adults) 5
  • Cephalexin: 250-500 mg four times daily (adults) 5
  • Pediatric dosing should be weight-based 5

For Suspected or Confirmed MRSA:

Consider MRSA coverage when there is failure to respond to first-line therapy, high local MRSA prevalence, or patient risk factors for CA-MRSA. 1

  • Clindamycin: 300-450 mg three times daily (adults) 5
  • Trimethoprim-sulfamethoxazole (TMP-SMX) 1, 5
  • Doxycycline: Not for children under 8 years 5

Critical pitfall: Penicillin alone is NOT effective for impetigo due to inadequate S. aureus coverage 5, 6


Comparative Efficacy

Topical mupirocin is slightly superior to oral erythromycin (93% vs 78.5% clinical efficacy) and should be preferred for localized disease. 4, 7

  • Topical antibiotics demonstrate better cure rates than placebo (pooled RR 2.24,95% CI 1.61-3.13) 7
  • Mupirocin and fusidic acid show equivalent efficacy (RR 1.03,95% CI 0.95-1.11) 7
  • Oral antibiotics have higher rates of side effects, primarily gastrointestinal 7

Treatment Duration and Monitoring

Complete the full antibiotic course even if symptoms improve quickly to prevent complications such as post-streptococcal glomerulonephritis. 1

  • Topical therapy: 5-7 days 1, 5
  • Oral therapy: 5-10 days 5
  • Re-evaluate if no improvement after 48-72 hours 5

Special Situations

Nasal Impetigo

  • Apply mupirocin 2% ointment to affected areas three times daily for 5-7 days 8
  • For recurrent infections: Mupirocin ointment twice daily in anterior nares for the first 5 days each month reduces recurrences by approximately 50% 8
  • Clindamycin 150 mg daily for 3 months may decrease subsequent infections by approximately 80% in persistent nasal colonization 8

Scalp Impetigo

  • Same treatment algorithm as other sites 5
  • Oral antibiotics preferred when multiple scalp sites are involved 5

Treatment Failure

Obtain cultures of vesicle fluid, pus, or erosions if treatment fails, MRSA is suspected, or recurrent infections occur. 5

  • Adjust therapy based on susceptibility results 5
  • Consider alternative diagnoses if not responding to appropriate therapy 5

Prevention Strategies

Maintain good personal hygiene as streptococcal organisms initially colonize unbroken skin before causing infection. 3

  • Keep lesions covered with clean, dry bandages to prevent spread 5
  • Address minor skin trauma, insect bites, and underlying conditions (eczema) promptly 3, 2
  • Avoid sharing personal items during active infection 2

Antimicrobial Resistance Considerations

Growing bacterial resistance rates worldwide necessitate judicious antibiotic selection and consideration of local resistance patterns. 2, 9

  • Methicillin-resistant S. aureus (MRSA) prevalence is increasing 2
  • Macrolide-resistant streptococcus and mupirocin-resistant streptococcus are documented 2
  • Erythromycin resistance rates are rising 6
  • Avoid topical disinfectants as they are inferior to antibiotics (RR 1.15,95% CI 1.01-1.32 favoring antibiotics) 7

Key Clinical Pearls

  • Impetigo typically resolves within 2-3 weeks without scarring, but treatment improves cosmesis, reduces discomfort, and prevents spread 2, 6
  • Complications are rare, with post-streptococcal glomerulonephritis being the most serious 2
  • Side effects from topical therapy are minimal compared to oral antibiotics 4, 7
  • Tetracyclines should never be used in children under 8 years of age 5

References

Guideline

Treatment of Impetigo

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Impetigo: diagnosis and treatment.

American family physician, 2014

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Scalp Impetigo

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnosis and treatment of impetigo.

American family physician, 2007

Research

Interventions for impetigo.

The Cochrane database of systematic reviews, 2012

Guideline

Treatment of Impetigo in the Nose

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Impetigo: A need for new therapies in a world of increasing antimicrobial resistance.

Journal of clinical pharmacy and therapeutics, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.